Design Therapeutics, Inc. (DSGN) stock forecast and price target
Price $10.47 · data as of November 13, 2026
12-month price target
Average target$21.57
Upside / downside+106.0%
Analysts7
ConsensusStrong buy
Low $19.00Average $21.57High $26.00
Gold marker: average target · white marker: today’s price ($10.47)
Analyst ratings
Strong buy 2Buy 6Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.34 | −9.8% | $0 |
| Next fiscal year ends December 31, 2027 | $-1.55 | −16.0% | $0 |
| Next quarter ends December 31, 2026 | $-0.40 | −46.3% | $0 |
| Quarter after ends March 31, 2027 | $-0.35 | −22.1% | $0 |
Consensus of the analysts covering Design Therapeutics, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Frequently asked questions
What is the Design Therapeutics stock price target?
The average 12-month target from 7 analysts is $21.57, 106.0% above the current price of $10.47 Targets range from $19.00 to $26.00.
Is Design Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 6 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Design Therapeutics expected to earn?
Analysts expect EPS of $-1.34 for the fiscal year ending December 31, 2026 and $-1.55 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.